SCHEMBL160650

SCHEMBL160650

CC(C)C[C@@](C)(N)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.45
GRM2 Q14416 2/20 0.44
GRM3 Q14832 1/20 0.44
ARG1 P05089 2/20 0.41
ARG2 P78540 2/20 0.41
NOS2 P35228 4/20 0.41
NOS1 P29475 2/20 0.41
BLM P54132 2/20 0.39
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
EGFR P00533 1/20 0.36
CYP1A2 P05177 1/20 0.36
FYN P06241 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181332 1.00 GGT1 (0.45) GGT1GRM2GRM3ARG1ARG2
SCHEMBL160649 1.00 GGT1 (0.45) GGT1GRM2GRM3ARG1ARG2
Hydrochloric Acid SCHEMBL8995745 0.98 GGT1 (0.43) GGT1GRM2GRM3ARG1ARG2
Hydrochloric Acid SCHEMBL8995749 0.98 GGT1 (0.43) GGT1GRM2GRM3ARG1ARG2
Hydrochloric Acid SCHEMBL1025465 0.98 GGT1 (0.43) GGT1GRM2GRM3ARG1ARG2
Hydrochloric Acid SCHEMBL5764217 0.98 GGT1 (0.43) GGT1GRM2GRM3ARG1ARG2
SCHEMBL2721337 0.83 ARG1 (0.50) GGT1GRM2GRM3ARG1ARG2
SCHEMBL497269 0.83 GGT1 (0.43) GGT1GRM2GRM3ARG1ARG2
SCHEMBL27601801 0.82 SLC7A5 (0.40) GGT1GRM2GRM3ARG1ARG2
SCHEMBL1300782 0.81 GABRR1 (0.43) GGT1GRM2GRM3ARG1ARG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1818 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013004716-A1 PEPTIDE BEADS UNIVERSITÄT BASEL (CH) 2013-01-10 WO claimed
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
US-7070969-B1 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis THE UNIVERSITY OF QUEENSLAND (AU) 2006-07-04 US claimed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
WO-2026090460-A1 MELANOCORTIN, GIP-R, AND GLP-1 RECEPTOR AGONISTS AND METHODS OF USE SEATTLE CHILDREN’S HOSPITAL (D/B/A SEATTLE CHILDREN’S RESEARCH INSTITUTE) (US) 2026-04-30 WO disclosed
US-12613237-B2 Biosensors for detecting arrestin signaling MONTANA MOLECULAR, LLC (US) 2026-04-28 US disclosed
US-20250361273-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC 2025-11-27 US disclosed
EP-4627079-A2 THERMOSTABLE BINDING SCAFFOLDS Nectagen, Inc. (US) 2025-10-08 EP disclosed
EP-4622997-A2 MELANOCORTIN AND GLP-1 RECEPTOR AGONISTS AND METHODS OF USE Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) 2025-10-01 EP disclosed
CN-120202191-A Inhibitors of prostate specific membrane antigen and uses thereof 上海先通生物科技有限公司 2025-06-24 CN disclosed
US-20250171497-A1 ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME BAUSCH HEALTH IRELAND LIMITED (IE) 2025-05-29 US disclosed
WO-1997012037-A1 A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-04-03 WO disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215895-A1 Therapeutic and carrier molecules PHKG1, PHKG2, DGKB GGT1 1211/4885GRM2 1733/4885GRM3 1478/4885
US-20250171497-A1 ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME GUCY1A1, GUCY1A2, GUCY1B1 GGT1 890/4885GRM2 650/4885GRM3 359/4885
US-12613237-B2 Biosensors for detecting arrestin signaling ARRB1, RGS19, GPR55 GGT1 2131/4885GRM2 1226/4885GRM3 1287/4885
US-20250361273-A1 METHODS AND COMPOSITIONS MC4R, GPR119, MC2R GGT1 2223/4885GRM2 264/4885GRM3 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.